Table 4 Results of the survey.

From: Participant perspective on the recall-by-genotype research approach: a mixed-method embedded study with participants of the CHRIS study

Answer n. (An) (Qn, qn)

Topic of the question

Results

Interpreted within the theme

A1 (Q2, q2)

After the invitation, thought about being a carrier of the variant associated with Parkinson’s disease

Yes

27

52.9

Information filter through personal experience

No

21

41.2

Not answered

3

5.9

A2 (Q3, q2)

Concern about being carrier of the Parkin gene variant

Very concerned

1

2

Concerned to some extent

11

21.6

A little concerned

17

33.3

Not at all concerned

17

33.3

I don’t know

3

5.9

Not answered

2

3.9

A3 (Q7, q2)

Perceived likelihood of not carrying the variant

Very likely

9

17.7

Rather likely

3

5.9

Neither likely nor unlikely

19

37.3

Rather unlikely

14

27.5

Very unlikely

5

9.8

Not answered

1

2

A4 (Q5a, q2)

Comparative risk perception of developing Parkinson’s disease following invitation (risk perception higher today compared to risk perception before receiving the invitation)

Do not agree

20

39.2

Rather not agree

6

11.8

Neither agree nor disagree

17

33.3

Rather agree

5

9.8

Agree

2

3.9

Not answered

1

2

A5 (Q5b, q2)

Comparative assessment of feeling worried about developing Parkinson’s disease following invitation: feeling more worried today compared to before receiving the invitation

Do not agree

21

41.2

Rather not agree

6

11.8

Neither agree nor disagree

15

29.4

Rather agree

7

13.7

Agree

0

0

Not answered

2

3.9

A6 (Q4, q2)

Self-assessment of the risk of developing Parkinson’s disease

Very high risk

1

2

Increased risk

5

9.8

Low risk

18

35.3

No risk

5

9.8

I don’t know

21

41.2

Not answered

1

2

A7 (Q8, q2)

Familial history of Parkinson’s disease

Yes

18

35.3

No

31

60.8

Not answered

2

2.9

A8 (Q1, q1)

Satisfaction with information received before participation

No, many questions were not answered

2

3.9

Stress relief mechanisms

No, some questions are still unclear

3

5.9

Yes, most of the questions were clarified

22

43.1

Yes, all the questions were answered

20

39.2

Not answered

4

7.8

A9 (Q10, q2)

Satisfaction with information received at the study center

No, many questions were not answered

0

0

No, some questions are still unclear

0

0

Yes, most of the questions were clarified

14

27.5

Yes, all the questions were answered

36

70.6

Not answered

1

2

A10 (Q11, q2)

Clarification of questions and doubts during participation

Yes

49

96.1

No

1

2

Not answered

1

2

A11 (Q13b, q2)

Disclosure of the disease under study

Yes

45

88.2

Targeted information matters

No

3

5.9

This is not important to me

0

0

Not answered

3

5.9

A12 (Q9, q2)

No return of genetic research results

That’s fine with me

42

82.4

Expectations on disclosure

I think that’s a pity

8

15.7

I don’t care

0

0

Not answered

1

2

A13 (Q6, q2)

Willingness to know the individual carrier status relative to Parkin

Yes

27

52.9

No

23

45.1

Not answered

1

2

A14 (Q13a, q2)

Evaluation of the practice of not disclosing the disease

Very negative

8

15.7

Rather negative

17

33.3

Partly negative/partly positive

16

31.4

Rather positive

8

15.7

Very positive

1

2

Not answered

1

2

A15 (Q13c, q2)

Impact of the type of disease in willingness to know the disease under study

Yes

27

52.9

No

23

45.1

Not answered

1

2

  1. For easy comparison with the original questions of the questionnaires (Supplementary Information 1), question number (Qn) and questionnaire number (qn) are also reported.